Outcome of Balloon Pulmonary Valvuloplasty in Patients With Congenital Pulmonary Stenosis in Terms of Reverse Right Ventricular Remodelling and Functional Exercise Capacity

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05828524
Collaborator
(none)
30
1
46.7
0.6

Study Details

Study Description

Brief Summary

A prospective of 30 patients with symptomatic severe congenital valvular pulmonary stenosis who are indicated for percutaneous balloon pulmonary valvuloplasty . the aim is to

    • evaluate electrical and mechanical remodeling of RV 6 months following balloon dilation
    • evaluate Functional capacity using 6MWT and SaO2 before and 6 months following BPV
Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Valvular pulmonary stenosis (PS), defined as an obstruction of blood flow at the level of the pulmonary valve, is a form of congenital heart disease, described in 0.6-0.8 out of 1000 live births.

    The main physiologic effect of valvular pulmonary stenosis (PS) is an increase in Right ventricular pressure proportional to the severity of obstruction. This elevation of RV pressure is accompanied by an increase in muscle mass where hyperplasia of the muscle cells with a concomitant increase in the number of capillaries occurs. In contrast, the adult myocardium responds with hypertrophy of the existing fibers, with no change in the capillary network. Percutaneous balloon pulmonary valvuloplasty (PBPV) is the procedure of choice for uncomplicated severe or symptomatic pulmonary stenosis. the aim is to

      • evaluate electrical and mechanical remodeling of RV 6 months following balloon dilation
      • evaluate Functional capacity using 6MWT and SaO2 before and 6 months following BPV

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Outcome of Balloon Pulmonary Valvuloplasty in Patients With Congenital Pulmonary Stenosis in Terms of Reverse Right Ventricular Remodeling and Functional Exercise Capacity
    Actual Study Start Date :
    Jan 10, 2021
    Anticipated Primary Completion Date :
    Dec 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. reverse Right ventricular remodeling [one year]

      reverse right ventricular remodeling detected by cardiac MRI and 2D echocardiography after

    2. functional exercise capacity [one year]

      assessment of functional exercise capacity by performing six minutes walk test

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • 1-Adult population with an age more than or equal to 16 years of age at time of procedure 2-Severe valvular Pulmonary stenosis defined as a PG max more than or equal to 64 mmHg measured by 2d echo before Procedure
    Exclusion Criteria:
    1. Patients with isolated supra-valvular and sub valvular pulmonary stenosis

    2. Patients with peripheral pulmonary stenosis.

    3. Patients with pulmonary stenosis if part of another congenital heart disease .

    4. Patients with organically diseased Tricuspid valve

    5. Patients with any significant shunt lesion which result in dilation in RV such as atrial septal defect.

    6. Patients with right ventricular dysfunction due to arrhythmogenic right ventricular dysplasia (ARVD) or non compaction

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of medicine Assiut university Assiut Egypt 71515

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Salah Eldin Mohammed Mostafa, Dr, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05828524
    Other Study ID Numbers:
    • BPVP
    First Posted:
    Apr 25, 2023
    Last Update Posted:
    Apr 25, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 25, 2023